Triple-S Management Corporation (GTS) Stock Competitors & Peer Comparison
See (GTS) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GTS | $35.99 | +1.04% | 0 | 10.41 | $3.46 | N/A |
| UNH | $426.09 | +0.64% | 387B | 26.08 | $16.34 | +2.08% |
| CVS | $107.47 | +0.91% | 137.1B | 15.20 | $7.07 | +2.48% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.42% |
| ELV | $373.11 | +0.07% | 80.9B | 12.69 | $29.39 | +1.85% |
| CI | $281.45 | -0.84% | 74.5B | 9.11 | $30.90 | +2.18% |
| HUM | $400.00 | -1.91% | 46.4B | 24.38 | $15.86 | +0.89% |
| CNC | $66.44 | +3.99% | 32.8B | 26.36 | $2.52 | N/A |
| MOH | $225.37 | +0.24% | 11.7B | 32.57 | $6.92 | N/A |
| OSCR | $29.10 | +0.83% | 7.5B | -49.28 | -$0.59 | N/A |
Stock Comparison
GTS vs UNH Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UNH has a market cap of 387B. Regarding current trading prices, GTS is priced at $35.99, while UNH trades at $426.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UNH's P/E ratio is 26.08. In terms of profitability, GTS's ROE is +0.07%, compared to UNH's ROE of +0.12%. Regarding short-term risk, GTS is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check UNH's competition here
GTS vs CVS Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CVS has a market cap of 137.1B. Regarding current trading prices, GTS is priced at $35.99, while CVS trades at $107.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CVS's P/E ratio is 15.20. In terms of profitability, GTS's ROE is +0.07%, compared to CVS's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CVS's competition here
GTS vs ANTM Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, GTS is priced at $35.99, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ANTM's P/E ratio is 18.99. In terms of profitability, GTS's ROE is +0.07%, compared to ANTM's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ANTM's competition here
GTS vs ELV Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ELV has a market cap of 80.9B. Regarding current trading prices, GTS is priced at $35.99, while ELV trades at $373.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ELV's P/E ratio is 12.69. In terms of profitability, GTS's ROE is +0.07%, compared to ELV's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ELV's competition here
GTS vs CI Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CI has a market cap of 74.5B. Regarding current trading prices, GTS is priced at $35.99, while CI trades at $281.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CI's P/E ratio is 9.11. In terms of profitability, GTS's ROE is +0.07%, compared to CI's ROE of +0.15%. Regarding short-term risk, GTS is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CI's competition here
GTS vs HUM Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, HUM has a market cap of 46.4B. Regarding current trading prices, GTS is priced at $35.99, while HUM trades at $400.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas HUM's P/E ratio is 24.38. In terms of profitability, GTS's ROE is +0.07%, compared to HUM's ROE of +0.06%. Regarding short-term risk, GTS is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check HUM's competition here
GTS vs CNC Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CNC has a market cap of 32.8B. Regarding current trading prices, GTS is priced at $35.99, while CNC trades at $66.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CNC's P/E ratio is 26.36. In terms of profitability, GTS's ROE is +0.07%, compared to CNC's ROE of -0.29%. Regarding short-term risk, GTS is less volatile compared to CNC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CNC's competition here
GTS vs MOH Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MOH has a market cap of 11.7B. Regarding current trading prices, GTS is priced at $35.99, while MOH trades at $225.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MOH's P/E ratio is 32.57. In terms of profitability, GTS's ROE is +0.07%, compared to MOH's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check MOH's competition here
GTS vs OSCR Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, OSCR has a market cap of 7.5B. Regarding current trading prices, GTS is priced at $35.99, while OSCR trades at $29.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas OSCR's P/E ratio is -49.28. In terms of profitability, GTS's ROE is +0.07%, compared to OSCR's ROE of -0.03%. Regarding short-term risk, GTS is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check OSCR's competition here
GTS vs ALHC Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, ALHC has a market cap of 4.3B. Regarding current trading prices, GTS is priced at $35.99, while ALHC trades at $20.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas ALHC's P/E ratio is 228.89. In terms of profitability, GTS's ROE is +0.07%, compared to ALHC's ROE of +0.11%. Regarding short-term risk, GTS is less volatile compared to ALHC. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check ALHC's competition here
GTS vs CLOV Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CLOV has a market cap of 2.4B. Regarding current trading prices, GTS is priced at $35.99, while CLOV trades at $4.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CLOV's P/E ratio is -38.50. In terms of profitability, GTS's ROE is +0.07%, compared to CLOV's ROE of -0.17%. Regarding short-term risk, GTS is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CLOV's competition here
GTS vs BHG Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, GTS is priced at $35.99, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas BHG's P/E ratio is -0.12. In terms of profitability, GTS's ROE is +0.07%, compared to BHG's ROE of +0.04%. Regarding short-term risk, GTS is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check BHG's competition here
GTS vs CABR Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, CABR has a market cap of 19.2M. Regarding current trading prices, GTS is priced at $35.99, while CABR trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas CABR's P/E ratio is -2.32. In terms of profitability, GTS's ROE is +0.07%, compared to CABR's ROE of -3.28%. Regarding short-term risk, GTS is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for GTS.Check CABR's competition here
GTS vs AET Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, AET has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas AET's P/E ratio is 9.57. In terms of profitability, GTS's ROE is +0.07%, compared to AET's ROE of +0.11%. Regarding short-term risk, GTS is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check AET's competition here
GTS vs MGLN Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, MGLN has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas MGLN's P/E ratio is 8.49. In terms of profitability, GTS's ROE is +0.07%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, GTS is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check MGLN's competition here
GTS vs UAM Comparison July 2026
GTS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GTS stands at 0. In comparison, UAM has a market cap of 0. Regarding current trading prices, GTS is priced at $35.99, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GTS currently has a P/E ratio of 10.41, whereas UAM's P/E ratio is 1.01. In terms of profitability, GTS's ROE is +0.07%, compared to UAM's ROE of +0.17%. Regarding short-term risk, GTS is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for GTS.Check UAM's competition here